Cost-Benefit of Minimally Invasive Staging of Non-Small Cell Lung Cancer: A Decision Tree Sensitivity Analysis

Journal of Thoracic Oncology - United States
doi 10.1097/jto.0b013e3181e8b2e6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Minimally Invasive Mediastinal Staging of Non-Small Cell Lung Cancer

Precision and Future Medicine
2018English

Staging Non-Small Cell Lung Cancer

Cancer Imaging
Nuclear MedicineRadiologyUltrasound TechnologyOncologyRadiologicalImagingMedicine
2007English

The Optimality of Different Strategies for Supplemental Staging of Non–Small-Cell Lung Cancer: A Health Economic Decision Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Minimally Invasive Staging of Esophageal Cancer

Annals of Cardiothoracic Surgery
SurgeryCardiovascular MedicineCardiology
2017English

Minimally Invasive Staging of Esophageal Cancer

ASVIDE
2017English

Quantifying the Benefit of Non-Small-Cell Lung Cancer Immunotherapy

The Lancet
Medicine
2019English

Thoroughness of Mediastinal Staging in Stage IIIA Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Quantifying the Benefit of Non-Small-Cell Lung Cancer Immunotherapy – Authors' Reply

The Lancet
Medicine
2019English

P3.01-081 Overall Survival (OS) of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) After Negative Invasive Mediastinal Staging

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy